Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

In vivo models: evaluating antifungal agents.

D M Dixon1

  • 1Loyola College, Baltimore, Maryland.

Methods and Findings in Experimental and Clinical Pharmacology
|November 1, 1987
PubMed
Summary

This study details in vivo antifungal models for drug testing against systemic fungal infections like candidiasis, cryptococcosis, and aspergillosis. It presents quantitative methods for evaluating drug efficacy in murine models of histoplasmosis and phaeohyphomycosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sigmodal in obstetrics; clinical observations with a report of three reactions.

Bulletin of the School of Medicine (Baltimore, Md.)·2010
Same author

Coccidioides immitis as a Select Agent of bioterrorism.

Journal of applied microbiology·2001
Same author

US-Japan workshops in medical mycology: past, present and future.

Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology·2001
Same author

Cutaneous infection with Mycobacterium xenopi.

Cutis·2001
Same author

The physician healer: ancient magic or modern science?

The British journal of general practice : the journal of the Royal College of General Practitioners·2000
Same author

Anaesthetic monitors--the vanishing trace.

Anaesthesia·1999

Area of Science:

  • Medical Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • In vivo antifungal models are crucial for evaluating drug efficacy against systemic fungal infections.
  • Standardized models are needed for reproducible and reliable drug screening.
  • Various fungal pathogens and antifungal agents require specific testing methodologies.

Purpose of the Study:

  • To summarize basic aspects of pure and applied studies involving in vivo antifungal models.
  • To describe a standard mouse model for acute, systemic fungal infection drug testing.
  • To present quantitative techniques for evaluating antifungal drug activity in murine models.

Main Methods:

  • A standard mouse model for establishing acute, systemic fungal infections.
  • Testing of representative mycoses (candidiasis, cryptococcosis, aspergillosis) with drugs like amphotericin B, 5-fluorocytosine, and ketoconazole.

Related Experiment Videos

  • Quantitative spleen culture technique for in vivo drug activity assessment in murine histoplasmosis and phaeohyphomycosis.

    • Main Results:

    • The described mouse model facilitates drug testing for acute systemic fungal infections.
    • Quantitative spleen cultures provide data on in vivo antifungal drug efficacy.
    • The model is applicable to evaluating drugs against systemic phaeohyphomycosis with CNS involvement.

    Conclusions:

    • In vivo antifungal models, particularly the described mouse model and quantitative culture techniques, are essential for drug development.
    • These models allow for the evaluation of drug efficacy against a range of fungal infections.
    • The methodology supports the assessment of antifungal agents in complex infections, including those with central nervous system involvement.